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Glycation potentiates 
neurodegeneration in models  
of Huntington’s disease
Hugo Vicente Miranda1,2, Marcos António Gomes2, Joana Branco-Santos3,4, Carlo Breda3, 
Diana F. Lázaro5, Luísa Vaqueiro Lopes2, Federico Herrera4, Flaviano Giorgini3 & 
Tiago Fleming Outeiro1,5,6
Protein glycation is an age-dependent posttranslational modification associated with several 
neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. By modifying amino-
groups, glycation interferes with folding of proteins, increasing their aggregation potential. Here, we 
studied the effect of pharmacological and genetic manipulation of glycation on huntingtin (HTT), the 
causative protein in Huntington’s disease (HD). We observed that glycation increased the aggregation 
of mutant HTT exon 1 fragments associated with HD (HTT72Q and HTT103Q) in yeast and mammalian 
cell models. We found that glycation impairs HTT clearance thereby promoting its intracellular 
accumulation and aggregation. Interestingly, under these conditions autophagy increased and the 
levels of mutant HTT released to the culture medium decreased. Furthermore, increased glycation 
enhanced HTT toxicity in human cells and neurodegeneration in fruit flies, impairing eclosion and 
decreasing life span. Overall, our study provides evidence that glycation modulates HTT exon-1 
aggregation and toxicity, and suggests it may constitute a novel target for therapeutic intervention  
in HD.
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder affecting 5–10 per 100 000 
individuals1–3. Its clinical features include progressive motor dysfunction, cognitive impairment, and psychiatric 
disturbance and dementia4. HD is caused by a CAG triplet repeat expansion in exon 1 of the HTT gene, which 
encodes a polyglutamine (polyQ) stretch in huntingtin (HTT) protein. The number of CAG repeats varies from 
16 to 35 in healthy individuals, while expansions of > 35 CAG repeats are found in HD patients1. The length of the 
polyQ tract in the protein modulates HTT aggregation, thereby causing cytotoxicity by mechanisms that are still 
not fully understood, with medium spiny neurons in the striatum particularly affected5.
Glucose is the major energy supply of neurons and is essential for their survival. However, impaired glucose 
metabolism can also damage neurons and lead to neurodegeneration. For example, diabetic patients who neglect 
their circulating glucose levels frequently develop severe neuropathy that results in the amputation of limbs6,7. 
Glucose metabolism drives the formation of by-products that are highly reactive with free amino-groups of pro-
teins. This non-enzymatic reaction, named glycation, induces the formation of advanced glycation end-products 
(AGEs) that frequently have deleterious effects on proteins8,9. For example, glycation has been reported in several 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, where it potentiates the aggregation 
and toxicity of proteins such as amyloid-β (Aβ ) and α -synuclein, respectively8,9.
Methylglyoxal (MGO) is an unavoidable by-product of glycolysis and the most reactive glycation agent. It is 
mainly produced by the non-enzymatic decomposition of the phosphate group of the triose phosphates (glycer-
aldeyde 3-phosphate and dihydroxyacetone phosphate)8. MGO can also arise from the interconversion between 
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glyceraldeyde 3-phosphate and dihydroxyacetone phosphate by the triose phosphate isomerase (Tpi), where the 
enediolate intermediate may leak from the active site of Tpi in a paracatalytical reaction10. Moreover, decreased 
Tpi activity results in an accumulation of dihydroxyacetone phosphate and MGO11,12. MGO is detoxified by the 
glyoxalase system [glyoxalases I (Glo1) and II (Glo2)] and by aldose reductases13. In particular, we previously 
showed that Glo1 inactivation induces a strong increase in MGO levels in yeast14. TPI1 deficiency increases 
the levels of DHAP15 and, consequently, increases the levels of MGO16,17. Notably, TPI deficiency in humans 
results in increased levels of MGO18. We recently demonstrated that glycation of α -synuclein - a central player 
in Parkinson’s disease - potentiates its aggregation and toxicity (submitted manuscript). Thus, we hypothesized 
that glycation might act as a common cellular mechanism modulating pathogenesis in several neurodegenerative 
diseases. Although HD is a genetic disorder, both genetic and environmental factors have been found to modulate 
the age of disease onset and severity of HD19–22. Although no direct correlation between glycation and the patho-
genesis of HD has been established thus far, the levels of the receptors for AGEs (RAGE) are increased in HD 
brains23 and in mouse models24. In addition, we also found that DJ-1 - an enzyme with glyoxalase and deglycase 
activity - modulates HTT toxicity25. Here, we show that glycation potentiates HTT aggregation, impairs protein 
clearance and increases neuronal loss in various established models of HD.
Results
Glycation induces HTT aggregation in yeast cells. We started by investigating the effects of MGO in a 
highly tractable yeast model of HD based on the expression of GFP-tagged HTT exon 1 fragments26 with normal 
(HTT25Q) or expanded (HTT72Q and HTT103Q) polyQ stretches, which lead to HTT aggregation and toxic-
ity27,28. Interestingly, we observed that glycating conditions (using MGO as the glycating agent) potentiated the 
formation of HTT72Q and HTT103Q inclusions in a dose-dependent manner, an effect that was potentiated by 
genetic deletion of Tpi (Fig. 1a,b).
We also modulated MGO levels genetically using Glo1 (Δ glo1) or Tpi (Δ tpi) knockout strains. Deletion of 
these genes increases the intracellular levels of MGO and promotes the accumulation of AGEs14,16,17. Remarkably, 
in protein extracts from Δ glo1 and Δ tpi strains, HTT was retained in the wells of SDS-PAGE gels (Fig. 1c), 
further demonstrating that glycation promotes aggregation of mutant HTT. HTT aggregation is also a func-
tion of HTT intracellular concentration, as overexpression of normal 25QHTT can also lead to aggregation29. 
Consistently, MGO also increased the intracellular HTT levels in a dose-dependent manner (Fig. 1c,d).
MGO increases HTT levels, aggregation, and toxicity in human cells. To further investigate the 
effects of glycation on HTT, we used transfected human H4 cells with variants of GFP-tagged HTT exon 1 frag-
ments encoding for 25 (HTT25Q) or 104 (HTT104Q) glutamines. To increase protein glycation, cells were treated 
with 0.5 mM of MGO, a working concentration widely used in various studies30–32. We found that this treatment 
increased protein glycation without increasing overall cytotoxicity (submitted manuscript). We confirmed that 
MGO treatment increased overall glycation levels of cells expressing either HTT25Q or HTT104Q (Fig. 2a). 
Moreover, using immunoprecipitation, we detected a consistent increase in the levels of AGEs in both HTT25Q 
and HTT104Q (Fig. 2a). Treatment with MGO induced a significant increase in the percentage of cells displaying 
HTT inclusions (1.33 fold) (Fig. 2b,c) and SDS-insoluble aggregates (1.5 fold), as assessed by filter trap assays 
(Fig. 2d,e). The levels of both HTT25Q and HTT104Q increased significantly under glycating conditions (1.33 
and 1.95 fold, respectively) (Fig. 2f,g). Notably, treatment of cells with MGO also specifically increased HTT104Q 
toxicity (1.5 fold) (Fig. 2h) and decreased cell viability of both HTT25Q and HTT104Q expressing cells (Fig. S1).
MGO impairs HTT clearance. Since MGO increased the intracellular levels of HTT, we next investigated 
the possible involvement of protein clearance pathways. First, we monitored the rate of clearance of the different 
HTT variants upon blocking de novo protein synthesis using cycloheximide (CHX). Interestingly, clearance of 
both HTT25Q (Fig. 3a,b) and HTT104Q (Fig. 3c,d) was impaired under MGO-induced glycating conditions.
Second, we assessed the effect of MGO in the autophagy lysosome pathway (ALP). For this, we blocked the 
ALP system with ammonium chloride (NH4Cl) in vehicle or MGO-treated cells, and evaluated the activation 
of ALP by measuring the accumulation of LC3-II levels33. Treatment of cells expressing HTT25Q with MGO 
reduced the activation of ALP (0.4 fold) (Fig. 3e,f). In contrast, in cells expressing HTT104Q we observed 
increased activation of ALP (6.6 fold) in response to MGO (Fig. 3g,h).
Third, we evaluated the effects of MGO on the UPS system using an unstable version of GFP (GFPu) that 
indicates the overall activity of the UPS34. Briefly, when the UPS is functioning properly, low levels of GFPu accu-
mulation are expected. As a positive control, we blocked the proteasome function with MG132 and observed a 
dose-dependent increase in the fluorescence levels, indicating proteasome inhibition (Fig. S2). The levels of GFPu 
were not altered in cells expressing either HTT25Q or HTT104Q upon MGO treatment (Fig. 3i,j).
Finally, we asked whether glycating conditions affected the cellular release of different HTT exon 1 vari-
ants. Conditioned media from HTT104Q-expressing cells treated with MGO showed a significant reduction 
in the total amount of HTT (less than 0.5 fold), but no changes were observed in the conditioned media from 
HTT25Q-expressing cells (Fig. 3k,l).
These results suggest that glycation impairs HTT clearance, causing it to accumulate and aggregate within 
cells.
Glycation enhances toxicity in Drosophila models of HD. Given that MGO increased HTT aggre-
gation and toxicity in cell models, we next investigated whether glycation also affected neuronal loss in vivo, 
employing a Drosophila model of HD based upon the pan-neuronal expression of a HTT exon 1 fragment 
with 93 or 20 glutamines (HTT93Q or HTT20Q) via the GAL4/UAS system35. HTT93Q flies exhibit a vari-
ety of HD-relevant phenotypes, including decreased lifespan, locomotor defects, degeneration of photoreceptor 
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Figure 1. Glycation increases HTT levels and inclusion formation in yeast. (a) Fluorescence micrographs of 
BY4741 (Ctrl), glo1Δ and tpiΔ yeast strains transformed with HTT 25Q, 72Q or 103Q variants fused to GFP 
(scale bar 20μ m). (b) % of yeast cells displaying HTT inclusions (at least n = 3 per condition). (c) Yeast protein 
extracts were immunoblotted with an anti-GFP antibody. Arrow indicates HTT aggregates. (d) Corresponding 
HTT levels are presented in arbitrary units (at least n = 3 per condition). Data in all panels are average ± SD, 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For (D), unpaired two-tailed t-test with equal SD.
www.nature.com/scientificreports/
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Figure 2. MGO induces HTT aggregation and toxicity in H4 cells. (a) Human H4 cells expressing HTT 25Q 
or 104Q were treated with vehicle (Ctrl) or MGO (0.5 mM) for 16 h. Cells were lysed and immunoprecipitated 
(IP) with GFP-trap (bottom panels). The whole cell lysates (WCL) and IP samples were probed for AGEs (left 
panels) or GFP (right panels). Arrow indicates HTT 25Q and HTT 104Q MW. Corresponding loading controls 
(β -actin) are presented (n = 3). (b) H4 cells expressing HTT 25Q or 104Q fused with GFP were treated with 
vehicle (Ctrl) or MGO (0.5 mM) for 16 h. After treatment, cells were probed with Hoechst and imaged in vivo. 
Fluorescence micrographs and (c) corresponding % of cells with HTT inclusions are presented. Scale barm 
50 μ m. (d) Representative filter trap assay and (e) corresponding HTT levels of cells expressing HTT 104Q 
treated with vehicle or MGO for 16 h and immunoblotted with an anti-GFP antibody. (f) Protein extracts were 
immunoblotted with an anti-GFP antibody. (g) The corresponding HTT levels are presented (at least n = 3 per 
condition). (h) Toxicity of vehicle (Ctrl) or MGO measured by LDH release (n = 3) and normalized to 25Q. 
Data in all panels are average ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For (c,e,g,h), unpaired 
two-tailed t-test with equal SD.
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Figure 3. Glycation impairs HTT clearance. H4 cells expressing HTT 25Q (a,b) or 104Q (c,d) for 24 h were 
pre-treated with vehicle (Ctrl) or MGO (0.5 mM) for 16 h. Cells were treated with vehicle or MGO for 24 h 
together with CHX. Protein extracts were probed for GFP and β -actin, for normalization, and protein levels are 
presented (at least n = 3). HTT 25Q (e,f) and 104Q (g,h) expressing cells were pre-treated with vehicle (Ctrl) 
or MGO (0.5 mM) for 16 h. Cells were treated with vehicle or MGO for 2 h together with vehicle (− ) or NH4Cl 
(+ ). Protein extracts were probed for LC3 (I and II) and β -actin. LC3-II levels (lower band) were normalized 
to β -actin and as a metric for autophagy induction, the difference between NH4Cl and vehicle treatments was 
calculated. The ratio between MGO and Ctrl is presented as autophagy induction ratio (at least n = 3). (i) HTT 
25Q and GFPu 104Q and GFPu cells were treated with vehicle (− ) or MGO (0.5 mM) (+ ) for 16 h. Protein 
extracts were probed for GFP and β -actin (at least n = 3). Arrow indicates GFPu. (j) Normalized GFPu levels are 
presented. (k) HTT 25Q or 104Q were treated with vehicle (− ) or MGO (0.5 mM) (+ ) for 16h. Fresh media was 
conditioned for 6 h in the same cells (− ) or (+ ) and probed in a dotblot system for GFP (n = 3). (l) Normalized 
Htt released levels are presented. Data in all panels are average ± SD, *p < 0.05, **p < 0.01. For (b,d,f,h,j), 
unpaired two-tailed t-test with equal SD.
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neurons (rhabdomeres), and impaired emergence of the adult fly from the pupal case (eclosion)36,37. We manip-
ulated glycation in fruit flies either via MGO administration or genetic knockdown of either Glo1 or Tpi. 
Importantly, silencing of Tpi or Glo1 in flies expressing HTT93Q displayed an overall increase in glycation and an 
increase in the levels of AGEs (Fig. 4a). Adult HTT93Q-expressing flies displayed a dose-dependent reduction in 
the number of rhabdomeres per ommatidium when treated with MGO for 7 days (Fig. 4b). Moreover, we found 
that treatment of HTT93Q larvae during development with MGO resulted in a significant reduction in the num-
ber of rhabdomeres upon eclosion (Fig. 4c). RNAi knockdown of either Glo1 or Tpi in WT flies did not modulate 
neurodegeneration (Fig. S3). However, in HTT93Q expressing flies, knockdown of either Glo1 or Tpi caused a 
significant increase in neurodegeneration of rhabdomeres at both 0 and 7 days after eclosion (Fig. 4d,e) when 
compared to their relative titration controls. Remarkably, we observed a significant reduction in the percentage 
of eclosion in both Glo1 and Tpi knockdown lines (Fig. 5a,b) and a 6-day reduction in the lifespan in the Glo1 
knockdown line (Fig. 5c,d). These results strongly suggest that glycation can act as an important environmental 
modifier of HTT toxicity and HD.
Figure 4. Knockdown of Glo1 or Tpi induces neurotoxicity and decreases lifespan and survival in HTT93Q 
expressing flies. (a) 100 heads of flies expressing Htt93Q and knocked down for Tpi, Glo1 or 3 M (as control) 
were lysed and immunoprecipitated with anti-HTT antibody (bottom panels). The whole protein lysates (WPL) 
(n = 3) and IP samples (n = 2) were probed for AGEs (left panels) or HTT (right panels). Arrow indicates 
HTT93Q MW. Corresponding loading controls (α -tubulin) are shown. (b) Adult flies expressing HTT93Q 
were treated with different concentrations of MGO. Quantification of mean rhabdomeres per ommatidium 
is presented. (c) Flies were treated during development with MGO. Quantification of rhabdomeres per 
ommatidium upon eclosion is presented. Number of rhabdomeres per ommatidium in HTT expressing flies 
with pan-neuronal knockdown of Glo1 (d) or Tpi (e) is presented at day 0 or 7 post-eclosion. 3M + Htt93Q and 
GFP + Htt93Q were used as titration controls for Glo1 and Tpi silencing lines, respectively. Data in all panels are 
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Newman-Keuls post-
hoc test.
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Figure 5. Knockdown of Glo1 or Tpi impairs development and reduces lifespan in flies. RNAi silencing of Glo1 
(a) or Tpi (b) caused a reduction in the percentage of flies emerging from the pupal case. Flies carrying a single 
copy of the driver (elavGAL4) are shown as a control. Data in panels (a,b) are mean ± SEM. Survival rate was 
evaluated in flies with pan-neuronal knockdown of Glo1 (c) or Tpi (d) in mutant HTT backgrounds (n = 100–150 
flies per genotype). 3M + Htt93Q and GFP + Htt93Q were used in experiments as titration controls for GloI 
and Tpi silencing lines, respectively. Htt93Q + Glo1 RNAi (mean = 6); Htt93Q + 3M (mean = 12); Htt93Q + Tpi 
a RNAi (mean = 12); Htt93Q + Tpi b RNAi (mean = 11.5); Htt93Q + GFP (mean = 13). *p < 0.05, **p < 0.01, 
****p < 0.0001; for (a,b) Ordinary one-way ANOVA with Newman-Keuls multiple comparisons test; for (c,d) 
Log-rank (Mantel-Cox) test.
www.nature.com/scientificreports/
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Discussion
The precise mechanisms through which HTT mutations cause HD are still unknown. However, accumulation of 
HTT plays an important role in the disease and strategies aimed at reducing its levels constitute attractive strate-
gies for therapeutic intervention and are currently being explored in ongoing clinical trials38.
Different posttranslational modifications (PTMs) are known to modulate the levels, aggregation propensity 
and clearance of HTT, and could play a role in the development of HD39–41. For example, phosphorylation of HTT 
on Ser13 and Ser16 is protective in mouse models of HD42 enhancing the clearance of HTT via the proteasome 
and chaperone-mediated autophagy43. Acetylation of Lys9 and Lys444 promotes HTT clearance via the autophagy 
lysosome pathway (ALP)44. On the other hand, SUMOylation leads to HTT accumulation and translocation into 
the nucleus45.
Using established yeast, mammalian cell and fly models of HD, we found that both pharmacological and 
genetic induction of glycation plays a deleterious role in HD models by decreasing HTT clearance, increasing 
the intracellular levels of HTT and enhancing its aggregation and toxicity, either directly or indirectly (through 
the increase in the levels of HTT). Impaired clearance of HTT via the proteasome was previously associated with 
HD2. Strikingly, we observed different effects of glycation on normal (25Q) vs. mutant (104Q) HTT variants. 
While glycation impaired the activation of the ALP system in cells expressing HTT25Q, we observed increased 
activation of the ALP system in cells expressing HTT104Q. Although we cannot completely exclude an indirect 
effect of general protein glycation, we clearly observed distinct phenotypes between 25Q and 104Q HTT. The 
increased ALP activation suggests a compensatory mechanism for the cell to cope with aggregated HTT that is 
normally cleared via the ALP system46,47.
Diabetes is a risk factor for neurodegenerative diseases such as Alzheimer’s and Parkinson’s8,9. A major con-
sequence of diabetes is glucose metabolism imbalance and consequent hyperglycemia. Glucose and its byprod-
ucts have the ability to react with amino groups, forming AGEs that can impact the function of target proteins. 
Glycation exacerbates the accumulation, aggregation and toxicity of Aβ and α -synuclein8,48. Therefore, it is rea-
sonable to hypothesize that glycation might constitute a common mechanism contributing to the development of 
neurodegenerative diseases by acting as a “second hit” that tips the proteostasis balance of cells, causing dysfunc-
tion of multiple essential cellular pathways, and leading to premature death. Interestingly, and in agreement with 
our hypothesis, drugs used for the treatment of diabetes were already shown to be protective in HD. For example, 
metformin was shown to prolong the survival of HD male mice49. In addition, exendin-4 decreased HTT aggrega-
tion, suppressed cellular pathology in both brain and pancreas, improved motor function, and extended survival 
in a mouse model of HD50. In fact, the prevalence of diabetes is higher in HD patients51,52. Mouse models of HD 
develop hyperglycemia53,54, possibly due to the accumulation of intranuclear HTT inclusions in pancreatic β cells 
that produce insulin55,56. Consistently, HD brains differentially express several proteins linked to type-2 diabe-
tes57. However, whether diabetes is a contributing factor to pathogenesis or a consequence of HD is still unclear, 
as is the role of HTT glycation.
Although activation of autophagy could clear aggregated proteins and is considered an important therapeutic 
approach for several neurodegenerative disorders58, autophagy could also lead to neuronal death. Overactivation 
of ALP can lead to apoptosis or autophagic cell death59. Therefore, promoting glycation in HTT104Q expressing 
cells might account for the observed increase in HTT cytotoxicity by overactivating the ALP.
We did not observe alterations in the UPS, suggesting that, under the conditions tested, glycation does 
not affect HTT clearance by the proteasome. Interestingly, we observed that glycation reduces the release of 
HTT104Q, which may account for the observed intracellular accumulation of HTT104Q, increased aggregation 
and toxicity.
In vivo, feeding of mutant HTT exon-1-expressing flies with MGO, reduced the number of rhabdomeres 
per omatidium, demonstrating a dose-dependent and selective effect. The deleterious effect of MGO was also 
observed in a reduction of eclosion, suggesting that glycation exacerbates HTT-toxicity during development. 
Importantly, genetic manipulation of pathways controlling MGO levels, through Glo1 or Tpi1 knockdown, also 
resulted in increased neurotoxicity of mutant HTT93Q, and reduced survival. In Tpi RNAi flies, we observed 
a significant reduction in eclosion, and in Glo1 RNAi flies we observed a significant reduction in eclosion and 
survival rate. Altogether, our data clearly suggest that increased glycation exacerbates the toxicity of mutant HTT, 
and that this can occur already during developmental stages.
In this study we demonstrate for the first time that glycation plays an important role in HTT homeostasis, 
contributing to its neurotoxicity, accumulation and aggregation, as well as potentiating several disease-relevant 
phenotypes in a Drosophila model of HD (Fig. 6). Therefore, we hypothesize that hyperglycemia, and the una-
voidable glycation of proteins including HTT, may not only be a consequence but also a contributing factor in 
HD pathogenesis.
Interestingly, we recently showed that DJ-1 overexpression protects against HTT toxicity in yeast and fruit 
flies25. Although mutations in the DJ-1 gene are associated with recessive forms of Parkinson’s disease, DJ-1 was 
recently described as an anti-MGO enzyme with glyoxalase activity60. Moreover, DJ-1 was also suggested to act 
as a protein deglycase that repairs MGO-glycated proteins61. These findings are consistent with our study, further 
supporting a connection between protein glycation and HD. Altogether, our study suggests that glycation might 
contribute to HTT dysfunction and that modulation of glycation may constitute a novel target for therapeutic 
intervention in HD.
Materials and Methods
HTT protein levels and aggregation in yeast. The parental Saccharomyces cerevisiae strain BY4741 
(MAT a, his3Δ , leu2Δ , met15Δ , ura3Δ ), and deletion mutants glo1Δ and tpiΔ strains were used (Euroscarf 
collection). Cells were grown and transformed as in ref. 13 using GFP fusion constructs with a mutant HTT 
fragment with an expanded polyQ stretch of either 25, 72 or 103 in p416 vector under the regulation of the GPD 
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promoter as in ref. 26. Protein extraction was performed as in ref. 13. Fluorescence microscopy was performed 
using a Zeiss Axiovert 200 M.
MGO purification. MGO was produced as described in ref. 14.
Immunoprecipitation, microscopy, immunoblotting, toxicity, viability and aggregation assays. 
H4 neuroglioma cells were maintained, grown and transfected with HTT exon-1 fragments with a polyQ expan-
sions of either 25 or 104 fused to GFP as in ref. 26. Twenty-four hours after HTT25Q or HTT104Q transfection, 
cells in 35 mm imaging dishes (Ibidi), 60 mm or 100 mm dishes (Corning) were treated with vehicle (PBS) or 
MGO (0.5 mM) for 16 h. Total protein lysates were obtained as in ref. 13. Htt was immunoprecipitated using 
GFP-trap (Chromotek) according to the manufacturer instructions. Widefield fluorescent microscope Zeiss 
Axiovert 200 M (Carl Zeiss MicroImaging) or point scanning confocal microscope Zeiss LSM 710 (Carl Zeiss 
MicroImaging) were used to visualize HTT inclusions. Immunobloting was performed according to stand-
ard procedures as in ref. 13 using the following antibodies: anti GFP (NeuroMab, P42212, 1:3000); anti AGEs 
(Cosmobio, KAL-KH-001, 1:500); anti LC3 (Nano Tools, 0260-100/LC3-2G6, 1:2000) and anti β -actin (Ambion, 
AM4302, 1:5000). Cytotoxicity was measured by means of the LDH kit (Clontech), following manufacturer´s 
instructions. Cell viability was determined using the MTT assay according to standard procedures. Evaluation of 
HTT aggregation profiles by filter retardation assay was performed as in ref. 62. Briefly, cellulose acetate mem-
branes retain aggregates that are not soluble in SDS (1%) and that are larger than 0.22 μ m.
HTT clearance assay. For CHX chase experiments, H4 cells were transfected as previously13 with either 
HTT25Q or HTT104Q. After 24 h, cells were treated with vehicle (PBS) or MGO (0.5 mM) for 16 h. Media was 
renewed and cells re-challenged with vehicle or MGO for 24 h in the presence of CHX (100 μ M, added at given 
time points). Protein extracts were immunobloted. Proteasome impairment was assessed as the amount of GFPu 
accumulation. H4 cells were cotransfected with E.V. with GFPu; HTT25Q with GFPu or HTT104Q with GFPu. 
24 h post transfection, media was renewed and cells treated with vehicle (PBS) or MGO (0.5 mM) for 16 h and 
processed for immunobloting with anti-GFP antibody (NeuroMab, P42212). As positive control, H4 cells were 
transfected with GFPu and treated with increasing concentrations of MG132 for 24 hours. GFPu average fluo-
rescence level was analyzed by epifluorescence microscopy. For autophagy impairment studies, H4 cells were 
transfected with HTT25Q or HTT104Q. 24 h post transfection, media was renewed and cells treated for 16 h with 
vehicle (PBS) or MGO (0.5 mM). Media was again renewed and cells were re-challenged with vehicle or MGO 
during autophagy blockage with ammonium chloride (20 mM) for 2 h. Autophagy activity was measured as the 
amount of accumulated LC3-II after treatment with autophagy blockers33. For HTT release studies, H4 cells, 
transfected with HTT25Q or HTT104Q for 24 h were treated with MGO (0.5 mM) for 16 h. Media was renewed, 
and cells were again treated with MGO (0.5 mM) for 6 h, media collected, applied onto nitrocellulose membranes 
(0.22 μ m, Millipore) using a dot blot apparatus, and immunobloted with anti-GFP by standard procedures.
Drosophila lines. Flies were raised at 25 °C in LD12:12 on standard maize food. The elav-GAL4 (c155) and 
w; UASeGFP; + (5431) lines were obtained from the Bloomington Stock Center (Bloomington, Indiana). The w; 
+ ; UASHTT93Q and w; + ; UASHTT20Q transgenic line was kindly provided by J. Lawrence Marsh and Leslie 
Thompson (University of California, Irvine)35. RNAi transgenic lines were obtained from the Vienna Drosophila 
RNAi Center (VDRC). For Glo1 knockdown, the 101560 line from the KK Library (phiC31-based transgenes at 
Figure 6. Schematic representation of the effects of MGO glycation in models of HD. Glycation increases 
HTT intracellular levels and inclusion formation in yeast and H4. Ultimately, it increases HTT-dependent 
toxicity, leading to neurodegeneration and reduced viability and lifespan in flies.
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a single, defined site) was used. For Tpi knockdown, two lines were employed from the GD Library (P-element 
based, random insertion sites): 25643 and 25644. The UASeGFP and w; 3M; + (carrying an empty vector located 
in the KK site) lines were used in the experiment as titration controls.
Immunoprecipitation of HTT expressed in flies. Flies were processed for IP 7 days post-eclosion. 
Briefly, heads were separated using standard procedures, and protein extracts prepared by vigorous homogeniza-
tion with a tissue grinder followed by liquid nitrogen freeze and thaw cycles. 750 μ g of protein were used for IP, as 
we previously described63. 10 μ l per IP of anti Htt antibody was used (Millipore, MAB5374). IP and whole protein 
lysate (WPL) were probed using anti AGEs (Cosmobio, KAL-KH-001, 1:500); anti-Htt (Millipore, MAB5374, 
1:1000) and anti α -tubulin (Sigma, T5168, 1:15000).
Drosophila eclosion and longevity assays. Eclosion of fly lines was assessed as previously described in 
ref. 64. Male flies carrying the elavGAL4 driver were crossed to virgin females carrying the UASHTT93Q trans-
gene in order to generate females expressing HTT93Q and control males in the F1 generation. 10–35 crosses were 
set up in separate vials for each condition and parental flies were removed 5 days after mating. The number of 
female or male progeny emerging was scored over 10 days post-eclosion and the percentage of eclosion per vial 
was calculated using the following ratio: (number of female/number of male flies) × 100. For longevity assays, 
newly emerged female flies of the desired genotype were collected and kept in groups of 10 in separate vials. Flies 
were moved to fresh food every 2–3 days and the number of dead individuals scored daily.
Treatment of Drosophila with MGO. MGO was dissolved in H2O and added to standard maize media at 
the required doses (10, 30, 100 or 300 μ M). For treatment during development, crosses were set up and flies were 
grown on standard maize media previously supplemented with MGO. Flies expressing the desired genotype were 
collected upon eclosion and analyzed for both eclosion percentage and rhabdomere number. For adult feeding 
experiments, newly emerged flies were transferred to MGO-supplemented food and moved daily to fresh vials 
with appropriate MGO treatment concentration. Rhabdomeres were scored in flies fed with different concentra-
tions of MGO during 7 days, newly emerged untreated flies and 7 days-old untreated flies.
Pseudopupil analysis. The number of visible rhabdomeres per ommatidium was measured as described 
in ref. 37. Briefly, the number of rhabdomeres was scored for a minimum of 50 ommatidia per fly, in at least 
12 flies per condition at day 0 or 7 post-eclosion. Heads from adult flies were removed and fixed to glass slides 
using clear fingernail polish and rhabdomeres were examined at 500X magnification using an Olympus BH2 light 
microscope.
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